46brooklyn Research
@46brooklyndata
Followers
2K
Following
317
Media
137
Statuses
1K
Our nation's prescription drug supply chain is sick. The cure starts with a healthy dose of data and transparency.
Ohio, USA
Joined July 2018
“Earlier this week, the data wizards at 46brooklyn Research released one of the best—and most disturbing—reports I’ve read in a while.” See what all the fuss is about: https://t.co/Hyb3CxlTfO
drugstorecowboy.com
How PBMs Evolved to Sell Drugs to Themselves.
0
9
17
Big PBMs to a T. Drug pricing isn't nearly as complex as they make it out to be. By muddying the water big PBMs & their VI affiliates suck billions out of the system. @46brooklyndata @_APCI
https://t.co/iMuNeJoPB5
0
0
3
“They are telling you they hate high prices, they are telling you they work to get the lowest prices. This data suggests the opposite is occurring.” @ikeswetlitz @jtozz
bloomberg.com
A little-known Cigna Group subsidiary that sells generic drugs charges prices that skew higher than many competing suppliers, according to a new analysis that raises questions about the company’s...
0
0
4
Last month, @A_Ciaccia joined @sarahkemond @CoraOpsahl and @brianreid for a discussion on American drug pricing dysfunction and @icer_review’s latest report on rising brand drug launch prices. Check out the excellent discussion here:
0
5
3
This drug pricing distortion was supposed to go extinct. It’s never been more alive. Our latest:
46brooklyn.com
This summer, we launched a new research work that examined the costs yielded by a reborn and evolved species of the prescription drug supply chain: drug companies who are also part of larger vertic...
0
1
4
Amazing. My good friends at @46brooklyndata continuing to do god's work! Just read these contracts and you'll see that the heart of the U.S. drug pricing lies here. Kudos to the lawyers for their creativity. 😧 https://t.co/xsfuB5EL9E
46brooklyn.com
1
3
5
“You either want big discounts or you want actual low prices … You can’t have both.” - @A_Ciaccia
https://t.co/nUVeutvRxS
@pharmalot
statnews.com
Bausch Health has exited Medicaid and a federal government drug discount scheme known as 340B, a step that suggests more drugmakers may do the same.
0
0
1
This week, 46brooklyn CEO Antonio Ciaccia led a panel discussion with Mark Cuban and Cynthia Fisher on how radical price transparency, eliminating misaligned incentives, and true cost-based pricing can help cure our nation’s plague of bloated prescription drug costs. 💊
1
8
20
Our Founder and Chairman, Cynthia Fisher, spoke at #AVBCC2025 in #NYC with @mcuban moderated by @A_Ciaccia! Patients win when transparency shines across all aspects of healthcare.
1
6
12
Pharma resists Trump’s MFN push while profiting from US patent extensions @chazplazz
medium.com
Tuesday 30th September 2025
0
1
1
“MFN is a nice goal, but until you unravel the drug pricing distortions and inconsistencies in the U.S., it feels impossible to achieve.” - @A_Ciaccia
https://t.co/M59C3D67Bg
medium.com
Tuesday 30th September 2025
0
4
4
Why CVS stopped sharing sales data on its leading Humira biosimilar @ZacharyBrennan
endpoints.news
CVS subsidiary Cordavis stops sharing Humira biosimilar sales data after becoming market leader with Hyrimoz, making biosimilar uptake tracking more difficult.
0
0
3
“The prices in the U.S. are real and fake at the same time.” - @A_Ciaccia
@kalltucker
usatoday.com
President Donald Trump announced 100% tariffs on brand drugs. Companies that build a U.S. manufacturing plant will be exempt.
0
3
7
New drug pricing report: 💊 281 brand drugs have new list prices 📈 Trikafta increased 7% and Xolair increased 4% 📉 Yuflyma decreased 71% 📊 For the first time in our tracking of generic drug costs, we see inflation Receipts:
46brooklyn.com
As a non-profit, we at 46brooklyn have made it our goal to provide insights into U.S. drug pricing data available in the public domain based upon the figures we are able to get our nerdy hands on....
0
0
0
Today, 46brooklyn CEO @A_Ciaccia keynoted the @EmplyrsForumIN All-Stakeholders Meeting to lay out drug channel fundamentals for employers, the inflated nature of drug prices, and the conflicted intermediaries who are supposed to insulate us from them.
0
1
3
Excellent @sam_vadas interview with my OG drug pricing tag team partner @EricPachman on how the often-bad business of healthcare may have become too big to fail
schwabnetwork.com
Eric Pachman breaks down the August jobs report. He notes that healthcare and social services are only 17% of jobs in the U.S. but is disproportionately growing new jobs in the U.S. labor market. The...
2
2
8
What do @BigRonColeman and @mcuban have in common? And how does it relate to curing drug pricing dysfunction? Find out in this episode 🎧
New Episode! "Behind the PBM Curtain: Antonio Ciaccia Exposes the Game" Episode Title: Behind the PBM Curtain: Antonio Ciaccia Exposes the Game Show Notes: In this compelling episode of Real Pharma … Player links & show notes:
0
1
3
Check out @A_Ciaccia’s insights on America’s addiction to inflated drug prices – and how nothing will materially change until we break the cycle.
PBMs under the microscope: • Gross-to-net bubble drives higher list prices • Vertical integration: PBMs own pharmacies & wholesalers • 340B incentives favor pricey drugs • Reform is coming—FTC probes & new models More: https://t.co/YnFFE3Gls5
#DrugPricing
0
3
10
BMS/Pfizer offer direct-to-consumer option for Eliquis @MyshkoDenise
managedhealthcareexecutive.com
Following in the footsteps of other pharmaceutical companies, Bristol Myers Squibb and Pfizer are offering Eliquis for cash-paying patients at a discount of 40% off the list price.
7
4
3
A little known federal drug program (340B) meant to subsidize coverage for the poor has grown to be the second largest behind Medicare Part D. There are no controls over how hospitals spend the money, leading to possible abuses. My latest —
ohiocapitaljournal.com
Cincinnati-based Bon Secours Mercy Health describes itself as a "ministry" that seeks to serve "the poor, dying and underserved." However, it's one of two Ohio "nonprofit" hospital systems to face...
0
2
3